These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

690 related items for PubMed ID: 16625682

  • 1. Design and synthesis of potent, highly selective vasopressin hypotensive agonists.
    Stoev S, Cheng LL, Manning M, Wo NC, Szeto HH.
    J Pept Sci; 2006 Sep; 12(9):592-604. PubMed ID: 16625682
    [Abstract] [Full Text] [Related]

  • 2. Synthesis and structure-activity investigation of novel vasopressin hypotensive peptide agonists.
    Manning M, Stoev S, Cheng LL, Wo NC, Chan WY.
    J Pept Sci; 1999 Nov; 5(11):472-90. PubMed ID: 10587312
    [Abstract] [Full Text] [Related]

  • 3. Design of peptide oxytocin antagonists with strikingly higher affinities and selectivities for the human oxytocin receptor than atosiban.
    Manning M, Cheng LL, Stoev S, Wo NC, Chan WY, Szeto HH, Durroux T, Mouillac B, Barberis C.
    J Pept Sci; 2005 Oct; 11(10):593-608. PubMed ID: 15880385
    [Abstract] [Full Text] [Related]

  • 4. Design of potent and selective agonists for the human vasopressin V1b receptor based on modifications of [deamino-cys1]arginine vasopressin at position 4.
    Cheng LL, Stoev S, Manning M, Derick S, Pena A, Mimoun MB, Guillon G.
    J Med Chem; 2004 Apr 22; 47(9):2375-88. PubMed ID: 15084136
    [Abstract] [Full Text] [Related]

  • 5. Design of oxytocin antagonists, which are more selective than atosiban.
    Manning M, Stoev S, Cheng LL, Wo NC, Chan WY.
    J Pept Sci; 2001 Sep 22; 7(9):449-65. PubMed ID: 11587184
    [Abstract] [Full Text] [Related]

  • 6. An investigation of position 3 in arginine vasopressin with aliphatic, aromatic, conformationally-restricted, polar and charged amino acids.
    Stoev S, Cheng LL, Olma A, Klis WA, Manning M, Sawyer WH, Wo NC, Chan WY.
    J Pept Sci; 1999 Mar 22; 5(3):141-53. PubMed ID: 10323558
    [Abstract] [Full Text] [Related]

  • 7. An exploration of the effects of L- and D-tetrahydroisoquinoline-3-carboxylic acid substitutions at positions 2, 3 and 7 in cyclic and linear antagonists of vasopressin and oxytocin and at position 3 in arginine vasopressin.
    Manning M, Cheng LL, Stoev S, Bankowski K, Przybyiski J, Klis WA, Sawyer WH, Wo NC, Chan WY.
    J Pept Sci; 1995 Mar 22; 1(1):66-79. PubMed ID: 9222985
    [Abstract] [Full Text] [Related]

  • 8. Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasopressin at positions 4 and 8.
    Pena A, Murat B, Trueba M, Ventura MA, Wo NC, Szeto HH, Cheng LL, Stoev S, Guillon G, Manning M.
    J Med Chem; 2007 Feb 22; 50(4):835-47. PubMed ID: 17300166
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Novel sst(4)-selective somatostatin (SRIF) agonists. 3. Analogues amenable to radiolabeling.
    Erchegyi J, Waser B, Schaer JC, Cescato R, Brazeau JF, Rivier J, Reubi JC.
    J Med Chem; 2003 Dec 18; 46(26):5597-605. PubMed ID: 14667214
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Discovery and design of novel vasopressin hypotensive peptide agonists.
    Manning M, Stoev S, Cheng LL, Wo NC, Chan WY.
    J Recept Signal Transduct Res; 1999 Dec 18; 19(1-4):631-44. PubMed ID: 10071789
    [Abstract] [Full Text] [Related]

  • 14. De novo design, synthesis, and pharmacology of alpha-melanocyte stimulating hormone analogues derived from somatostatin by a hybrid approach.
    Han G, Haskell-Luevano C, Kendall L, Bonner G, Hadley ME, Cone RD, Hruby VJ.
    J Med Chem; 2004 Mar 11; 47(6):1514-26. PubMed ID: 14998337
    [Abstract] [Full Text] [Related]

  • 15. Potent V2/V1a vasopressin antagonists with C-terminal ethylenediamine-linked retro-amino acids.
    Manning M, Przybylski J, Grzonka Z, Nawrocka E, Lammek B, Misicka A, Cheng LL, Chan WY, Wo NC, Sawyer WH.
    J Med Chem; 1992 Oct 16; 35(21):3895-904. PubMed ID: 1433200
    [Abstract] [Full Text] [Related]

  • 16. Identification of putative agouti-related protein(87-132)-melanocortin-4 receptor interactions by homology molecular modeling and validation using chimeric peptide ligands.
    Wilczynski A, Wang XS, Joseph CG, Xiang Z, Bauzo RM, Scott JW, Sorensen NB, Shaw AM, Millard WJ, Richards NG, Haskell-Luevano C.
    J Med Chem; 2004 Apr 22; 47(9):2194-207. PubMed ID: 15084118
    [Abstract] [Full Text] [Related]

  • 17. Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents.
    Manning M, Stoev S, Chini B, Durroux T, Mouillac B, Guillon G.
    Prog Brain Res; 2008 Apr 22; 170():473-512. PubMed ID: 18655903
    [Abstract] [Full Text] [Related]

  • 18. Synthesis and some pharmacological properties of potent and selective antagonists of the vasopressor (V1-receptor) response to arginine-vasopressin.
    Manning M, Stoev S, Bankowski K, Misicka A, Lammek B, Wo NC, Sawyer WH.
    J Med Chem; 1992 Jan 24; 35(2):382-8. PubMed ID: 1531076
    [Abstract] [Full Text] [Related]

  • 19. Structure-activity relationships of the unique and potent agouti-related protein (AGRP)-melanocortin chimeric Tyr-c[beta-Asp-His-DPhe-Arg-Trp-Asn-Ala-Phe-Dpr]-Tyr-NH2 peptide template.
    Wilczynski A, Wilson KR, Scott JW, Edison AS, Haskell-Luevano C.
    J Med Chem; 2005 Apr 21; 48(8):3060-75. PubMed ID: 15828845
    [Abstract] [Full Text] [Related]

  • 20. Design and synthesis of highly selective in vitro and in vivo uterine receptor antagonists of oxytocin: comparisons with Atosiban.
    Manning M, Miteva K, Pancheva S, Stoev S, Wo NC, Chan WY.
    Int J Pept Protein Res; 1995 Apr 21; 46(3-4):244-52. PubMed ID: 8537178
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 35.